1. Medtech Insight

PharmChem gets US approval for sweat patch:

PharmChem (US) has received FDA market approval for its PharmChek sweat patch drug testing system for detecting the use of cocaine, opiates, and amphetamines (see Clinica No 663, p 20). "We hope to gain initial acceptance of PharmChek in criminal justice and drug treatment markets in 1995," says Jay Whitney, PharmChem's president and CEO. Future planned applications of the patch include the continuous monitoring of the use of alcohol while the patch is worn and the detection of drug abuse after the patch has been worn for only 20 to 30 minutes.

PharmChem (US) has received FDA market approval for its PharmChek sweat patch drug testing system for detecting the use of cocaine, opiates, and amphetamines (see Clinica No 663, p 20). "We hope to gain initial acceptance of PharmChek in criminal justice and drug treatment markets in 1995," says Jay Whitney, PharmChem's president and CEO. Future planned applications of the patch include the continuous monitoring of the use of alcohol while the patch is worn and the detection of drug abuse after the patch has been worn for only 20 to 30 minutes.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Cardiology And PTA Procedures In Germany’s Expanded Hybrid DRGs List 2026

 
• By Ashley Yeo

2026 reimbursement calculations for the list of hybrid DRGs – a mechanism to incentivize day cases over inpatient surgery – will be issued in few weeks’ time. The medtech industry has made its demands known.

Deals Shaping The Medtech And Diagnostics Industries, July 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By Elizabeth Orr

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.